Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Study of JNJ-41443532 in Type 2 Diabetics
4-Week Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-41443532 in Males and Females With Type 2 Diabetes
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
Study of JNJ-41443532 in Type 2 Diabetics
4-Week Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-41443532 in Males and Females With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Comparison of Glycemic Control in Obese Subjects With Diabetes Using the BD Ultra-Fineâ„¢ Nano 4mm x 32G Pen Needle, and Either the BD Ultra-Fineâ„¢ Short 8mm x 31G Pen Needle or the BD Ultra Fineâ„¢ 12.7mm x 29G Pen Needle
Status: Archived
AMCR Institute, Inc.
mi
from
Oceanside-Escondido, CA
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Comparison of Glycemic Control in Obese Subjects With Diabetes Using the BD Ultra-Fineâ„¢ Nano 4mm x 32G Pen Needle, and Either the BD Ultra-Fineâ„¢ Short 8mm x 31G Pen Needle or the BD Ultra Fineâ„¢ 12.7mm x 29G Pen Needle
Status: Archived
Updated: 1/1/1970
AMCR Institute, Inc.
mi
from
Oceanside-Escondido, CA
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Comparison of Glycemic Control in Obese Subjects With Diabetes Using the BD Ultra-Fineâ„¢ Nano 4mm x 32G Pen Needle, and Either the BD Ultra-Fineâ„¢ Short 8mm x 31G Pen Needle or the BD Ultra Fineâ„¢ 12.7mm x 29G Pen Needle
Status: Archived
Atlanta Diabetes Associates
mi
from
Atlanta, GA
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Comparison of Glycemic Control in Obese Subjects With Diabetes Using the BD Ultra-Fineâ„¢ Nano 4mm x 32G Pen Needle, and Either the BD Ultra-Fineâ„¢ Short 8mm x 31G Pen Needle or the BD Ultra Fineâ„¢ 12.7mm x 29G Pen Needle
Status: Archived
Updated: 1/1/1970
Atlanta Diabetes Associates
mi
from
Atlanta, GA
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Comparison of Glycemic Control in Obese Subjects With Diabetes Using the BD Ultra-Fineâ„¢ Nano 4mm x 32G Pen Needle, and Either the BD Ultra-Fineâ„¢ Short 8mm x 31G Pen Needle or the BD Ultra Fineâ„¢ 12.7mm x 29G Pen Needle
Status: Archived
International Diabetes Center (IDC)
mi
from
Minneapolis, MN
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Comparison of Glycemic Control in Obese Subjects With Diabetes Using the BD Ultra-Fineâ„¢ Nano 4mm x 32G Pen Needle, and Either the BD Ultra-Fineâ„¢ Short 8mm x 31G Pen Needle or the BD Ultra Fineâ„¢ 12.7mm x 29G Pen Needle
Status: Archived
Updated: 1/1/1970
International Diabetes Center (IDC)
mi
from
Minneapolis, MN
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Comparison of Glycemic Control in Obese Subjects With Diabetes Using the BD Ultra-Fineâ„¢ Nano 4mm x 32G Pen Needle, and Either the BD Ultra-Fineâ„¢ Short 8mm x 31G Pen Needle or the BD Ultra Fineâ„¢ 12.7mm x 29G Pen Needle
Status: Archived
Diabetes and endocrinology Center of WNY
mi
from
Buffalo, NY
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Comparison of Glycemic Control in Obese Subjects With Diabetes Using the BD Ultra-Fineâ„¢ Nano 4mm x 32G Pen Needle, and Either the BD Ultra-Fineâ„¢ Short 8mm x 31G Pen Needle or the BD Ultra Fineâ„¢ 12.7mm x 29G Pen Needle
Status: Archived
Updated: 1/1/1970
Diabetes and endocrinology Center of WNY
mi
from
Buffalo, NY
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Comparison of Glycemic Control in Obese Subjects With Diabetes Using the BD Ultra-Fineâ„¢ Nano 4mm x 32G Pen Needle, and Either the BD Ultra-Fineâ„¢ Short 8mm x 31G Pen Needle or the BD Ultra Fineâ„¢ 12.7mm x 29G Pen Needle
Status: Archived
Hackensack Univeristy Medical Center
mi
from
Hackensack, NJ
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Comparison of Glycemic Control in Obese Subjects With Diabetes Using the BD Ultra-Fineâ„¢ Nano 4mm x 32G Pen Needle, and Either the BD Ultra-Fineâ„¢ Short 8mm x 31G Pen Needle or the BD Ultra Fineâ„¢ 12.7mm x 29G Pen Needle
Status: Archived
Updated: 1/1/1970
Hackensack Univeristy Medical Center
mi
from
Hackensack, NJ
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Comparison of Glycemic Control in Obese Subjects With Diabetes Using the BD Ultra-Fineâ„¢ Nano 4mm x 32G Pen Needle, and Either the BD Ultra-Fineâ„¢ Short 8mm x 31G Pen Needle or the BD Ultra Fineâ„¢ 12.7mm x 29G Pen Needle
Status: Archived
University Diabetes and Endocrine Consultants
mi
from
Chattanooga, TN
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Comparison of Glycemic Control in Obese Subjects With Diabetes Using the BD Ultra-Fineâ„¢ Nano 4mm x 32G Pen Needle, and Either the BD Ultra-Fineâ„¢ Short 8mm x 31G Pen Needle or the BD Ultra Fineâ„¢ 12.7mm x 29G Pen Needle
Status: Archived
Updated: 1/1/1970
University Diabetes and Endocrine Consultants
mi
from
Chattanooga, TN
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Comparison of Glycemic Control in Obese Subjects With Diabetes Using the BD Ultra-Fineâ„¢ Nano 4mm x 32G Pen Needle, and Either the BD Ultra-Fineâ„¢ Short 8mm x 31G Pen Needle or the BD Ultra Fineâ„¢ 12.7mm x 29G Pen Needle
Status: Archived
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Comparison of Glycemic Control in Obese Subjects With Diabetes Using the BD Ultra-Fineâ„¢ Nano 4mm x 32G Pen Needle, and Either the BD Ultra-Fineâ„¢ Short 8mm x 31G Pen Needle or the BD Ultra Fineâ„¢ 12.7mm x 29G Pen Needle
Status: Archived
Updated: 1/1/1970
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Birmingham, AL
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Birmingham, AL
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Long Beach, CA
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Long Beach, CA
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Arvada, CO
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Arvada, CO
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
New London, CT
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
New London, CT
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Rhode Island Hospital
mi
from
Providence, RI
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Rhode Island Hospital
mi
from
Providence, RI
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Darien Pediatric Associates
mi
from
Darien, CT
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Darien Pediatric Associates
mi
from
Darien, CT
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Chicago, IL
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Chicago, IL
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Indianapolis, IN
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Indianapolis, IN
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Topeka, KA
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Topeka, KA
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Portland, ME
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Portland, ME
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Hyattsville, MD
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Hyattsville, MD
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
North Dartmouth, MA
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
North Dartmouth, MA
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Detroit, MI
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Detroit, MI
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Kansas City, MO
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Kansas City, MO
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Newark, NJ
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Newark, NJ
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
New York, NY
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
New York, NY
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Morehead City, NC
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Morehead City, NC
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
St. Luke Whiteside Research
mi
from
Duluth, MN
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
St. Luke Whiteside Research
mi
from
Duluth, MN
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Tulsa, OK
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Tulsa, OK
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Philadelphia, PA
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Philadelphia, PA
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Charleston, SC
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Charleston, SC
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Rapid City, SD
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Rapid City, SD
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Memphis, TN
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Memphis, TN
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Fort Worth, TX
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Fort Worth, TX
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Salt Lake City, UT
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Salt Lake City, UT
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Arlington, VA
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Arlington, VA
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Spokane, WA
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Spokane, WA
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Martinsburg, WV
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Martinsburg, WV
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Novo Nordisk Clinical Trial Call Center
mi
from
Milwaukee, WI
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
A 26-week Randomised, Controlled, Open Label, Multicentre, Multinational, Treat to Target Trial Investigating the Impact of Dietary Intervention on Weight Change and the Relationship Between Weight Change and Baseline Body Mass Index (BMI) in Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) Initiating Insulin Therapy With Insulin Detemir in Combination With Metformin Levemir DIET
Status: Archived
Updated: 1/1/1970
Novo Nordisk Clinical Trial Call Center
mi
from
Milwaukee, WI
Partners in Care Diabetes Self-management Intervention
Specific Aim 3: Partners in Care Randomized Controlled Trial
Status: Archived
University of Hawaii
mi
from
Honolulu, HI
Partners in Care Diabetes Self-management Intervention
Specific Aim 3: Partners in Care Randomized Controlled Trial
Status: Archived
Updated: 1/1/1970
University of Hawaii
mi
from
Honolulu, HI
Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus
Phase 1/2a, Randomized, Double-Blind Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of PB1023 Injection Following Single and Multiple Ascending Subcutaneous Doses in Adult Subjects With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Diablo Clinical
mi
from
Walnut Creek, CA
Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus
Phase 1/2a, Randomized, Double-Blind Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of PB1023 Injection Following Single and Multiple Ascending Subcutaneous Doses in Adult Subjects With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Updated: 1/1/1970
Diablo Clinical
mi
from
Walnut Creek, CA
Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus
Phase 1/2a, Randomized, Double-Blind Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of PB1023 Injection Following Single and Multiple Ascending Subcutaneous Doses in Adult Subjects With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
University of Minnesota (UMN)
mi
from
Minneapolis, MN
Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus
Phase 1/2a, Randomized, Double-Blind Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of PB1023 Injection Following Single and Multiple Ascending Subcutaneous Doses in Adult Subjects With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Updated: 1/1/1970
University of Minnesota (UMN)
mi
from
Minneapolis, MN
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia
Status: Archived
Radiant Research Inc.
mi
from
Chicago, IL
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia
Status: Archived
Updated: 1/1/1970
Radiant Research Inc.
mi
from
Chicago, IL
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia
Status: Archived
Clinical Trial Facility
mi
from
Kansas City, KA
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Kansas City, KA
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia
Status: Archived
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia
Status: Archived
Clinical Trial Facility
mi
from
St Louis, MO
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
St Louis, MO
Safety Study of BMS-903452 in Healthy Subjects (Part A) and Subjects With Type 2 Diabetes Mellitus (Part B)
A Randomized, Double-Blinded, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-903452 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
Status: Archived
Local Institution
mi
from
Lexington, KY
Safety Study of BMS-903452 in Healthy Subjects (Part A) and Subjects With Type 2 Diabetes Mellitus (Part B)
A Randomized, Double-Blinded, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-903452 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Local Institution
mi
from
Lexington, KY
Safety Study of BMS-903452 in Healthy Subjects (Part A) and Subjects With Type 2 Diabetes Mellitus (Part B)
A Randomized, Double-Blinded, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-903452 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
Status: Archived
PPD Development
mi
from
Austin, TX
Safety Study of BMS-903452 in Healthy Subjects (Part A) and Subjects With Type 2 Diabetes Mellitus (Part B)
A Randomized, Double-Blinded, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-903452 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
PPD Development
mi
from
Austin, TX
Effect of Whole Grain Diet on Insulin Sensitivity, Advanced Glycation End Products and Inflammatory Markers in Pre-diabetes
Effect of Whole Grain Diet on Insulin Sensitivity, Advanced Glycation End Products and Inflammatory Markers in Pre-diabetes
Status: Archived
Mount Sinai Hospital
mi
from
New York, NY
Effect of Whole Grain Diet on Insulin Sensitivity, Advanced Glycation End Products and Inflammatory Markers in Pre-diabetes
Effect of Whole Grain Diet on Insulin Sensitivity, Advanced Glycation End Products and Inflammatory Markers in Pre-diabetes
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
mi
from
New York, NY
Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies
Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies (PATIENT)
Status: Archived
Center for Health Research, Kaiser Permanente Southeast
mi
from
Atlanta, GA
Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies
Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies (PATIENT)
Status: Archived
Updated: 1/1/1970
Center for Health Research, Kaiser Permanente Southeast
mi
from
Atlanta, GA
Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies
Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies (PATIENT)
Status: Archived
Center for Health Research, Kaiser Permanente Hawaii
mi
from
Honolulu, HI
Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies
Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies (PATIENT)
Status: Archived
Updated: 1/1/1970
Center for Health Research, Kaiser Permanente Hawaii
mi
from
Honolulu, HI
Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies
Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies (PATIENT)
Status: Archived
Center for Health Research, Kaiser Permanente Northwest
mi
from
Portland, OR
Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies
Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies (PATIENT)
Status: Archived
Updated: 1/1/1970
Center for Health Research, Kaiser Permanente Northwest
mi
from
Portland, OR